- Home
- INZY vs QBTS Comparison
INZY vs QBTS Comparison
Compare INZY & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- QBTS
- Stock Information
- Founded
- INZY 2015
- QBTS 1999
- Country
- INZY United States
- QBTS Canada
- Employees
- INZY N/A
- QBTS N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- QBTS Retail: Computer Software & Peripheral Equipment
- Sector
- INZY Health Care
- QBTS Technology
- Exchange
- INZY Nasdaq
- QBTS Nasdaq
- Market Cap
- INZY 188.2M
- QBTS 1.4B
- IPO Year
- INZY 2020
- QBTS N/A
- Fundamental
- Price
- INZY $1.36
- QBTS $5.83
- Analyst Decision
- INZY Strong Buy
- QBTS Strong Buy
- Analyst Count
- INZY 8
- QBTS 6
- Target Price
- INZY $17.75
- QBTS $6.38
- AVG Volume (30 Days)
- INZY 1.0M
- QBTS 98.8M
- Earning Date
- INZY 03-11-2025
- QBTS 03-27-2025
- Dividend Yield
- INZY N/A
- QBTS N/A
- EPS Growth
- INZY N/A
- QBTS N/A
- EPS
- INZY N/A
- QBTS N/A
- Revenue
- INZY N/A
- QBTS $9,424,000.00
- Revenue This Year
- INZY N/A
- QBTS $4.86
- Revenue Next Year
- INZY N/A
- QBTS $64.04
- P/E Ratio
- INZY N/A
- QBTS N/A
- Revenue Growth
- INZY N/A
- QBTS 14.27
- 52 Week Low
- INZY $1.24
- QBTS $0.75
- 52 Week High
- INZY $7.80
- QBTS $11.41
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- QBTS 47.95
- Support Level
- INZY $1.35
- QBTS $5.39
- Resistance Level
- INZY $1.62
- QBTS $6.39
- Average True Range (ATR)
- INZY 0.13
- QBTS 0.78
- MACD
- INZY 0.04
- QBTS -0.12
- Stochastic Oscillator
- INZY 32.89
- QBTS 56.47
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the Company's LeapTM cloud service.